In 2019, about 1.5 million coronary stents will be used in China, with a cost of about 15 billion, accounting for one tenth of the total cost of high-value consumables in China. It is expected that soul bargaining or reappearance of similar drugs will be carried out at national level.
The final price of coronary stent products won the bid in the centralized procurement will be less than 2850 yuan. Before, the online prices of corresponding products of enterprises participating in centralized procurement ranged from 7600 yuan to 23000 yuan, and the import price was generally much higher than that of domestic products. Compared with the highest price of 23000 yuan, 2850 yuan decreased by 88%.
Photo source: Photo Gallery
Coronary stent is often said to be the heart stent, in the treatment of heart disease, the use rate is very high.
On the evening of last Friday (October 16), Shanghai Sunshine pharmaceutical procurement network released the procurement document of national organization of coronary stent concentration volume (hereinafter referred to as the document). This is another major event that affects the continuous attention of the industry after the centralized purchase of drugs.
According to the document, the scope of products involved in this round of centralized purchase is listed coronary drug-eluting stent system with Chinese medical device registration certificate, which is made of cobalt chromium alloy or platinum chromium alloy, and the drug loading type is rapamycin and its derivatives. Among the products intended to purchase, a total of 12 enterprises and 27 registered products will compete to enter the final list. The total number of intended purchases in the first year was 1074700, which was accumulated by 80% of the total purchase demand submitted by medical institutions in the alliance area. The cycle of this centralized procurement is 2 years, and the date of submitting the declared price is November 5.
Among the 12 enterprises, domestic coronary stent manufacturers include minimally invasive medical (00853, HK), Lepu medical (300003, SZ), lanfan medical (002382, SZ), xinlitai (002294, SZ), etc. Corresponding to the first year, there were 738600 intended purchases, accounting for 68.73% of the total.
Although there are 12 manufacturers with 27 products competing, only the top 10 products will be the first to be shortlisted. The ranking rule is to determine the ranking according to the order of product application quotation from low to high. The lowest quotation is the first, the second lowest is the second, and so on.
There are two provisions on products to be selected in the document, one of which is the application price is less than 1.8 times of the lowest product application price, and the other is the application price is more than 1.8 times of the lowest product application price, but less than 2850 yuan. This means that the final price of coronary stents will be lower than 2850 yuan.
However, according to Guosheng Securities Research Report, the online prices of the corresponding products of various enterprises in the first year of intended purchase range from 7600 yuan to 23000 yuan, and the online price of coronary stents of imported enterprises is generally much higher than that of domestic enterprises. At the same time, Societe Generale Securities Research Report predicts that the price competition will be more intense, and the winning price will probably affect the existing ex factory price system of coronary stents.
It is worth noting that October 19 is the first trading day after the above information is released, and the stock prices of coronary stent related enterprises in the secondary market fluctuated significantly. Minimally invasive medical shares fell 11.62% to HK $28.85; Lepu medical shares fell 8.83% to 31.28 yuan; lanfan medical shares fell 3.88% to 24.99 yuan; and xinlitai shares fell 5.29% to 31.70 yuan.
As of October 20, the above four stocks still fell collectively.
The intention products account for the companys revenue) is not very large, and the company has several other supports on the market. Ms. Hu introduced that Lepu medical intends to purchase cobalt based alloy rapamycin eluting stent system in the document, which is a product of the companys layout. It can cover a lot of diseases, but its unit price will be relatively low.
Ms. Hu introduced the other two products to the reporter. One is the product that accounts for a large proportion of the companys revenue, and the other is the new product that the company is pushing. The technical content of these two products is more advanced than that of Lepu medical intention purchase in the document, and they belong to medium and high-end products.
Facing the pressure from foreign investors of centralized mining
In the first year, the total number of intention to purchase coronary stents was 1074700. The price and use of the selected products in the centralized procurement of coronary stents is expected to be implemented in January 2021, which will affect the market of tens of billion yuan.
Some industry insiders told reporters that for high-value consumables and equipment enterprises, if they fail to win the bid, the pressure will be greater than that of pharmaceutical enterprises, because high-value consumables are basically used in clinical use in large hospitals, and there is no pharmacy market. If it fails to win the bid, only private hospitals will remain in the market outside the medical institutions in the alliance area.
Photo source: Photo Gallery
Ms. Hu of Lepu medical marketing department told reporters that although patients in different regions have different demands for products at various prices, the domestic products of the same kind selected by the company for purchase in the document have already accounted for more than 30% of all domestic products of the same type.
Zhan Jincheng, marketing general manager of aozida medical device service group, introduced to reporters that the clinical application of coronary stent has been more than 30 years. The product involved in this centralized purchase is a standardized product that has been used for many years. At present, the major manufacturers at home and abroad have produced the products, and the technology gap is not big.
However, in Zhan Jinchengs view, although the price of imported products was higher before, in fact, the purchase cost of products was lower than that of domestic enterprises because foreign businessmen had higher sales volume in the larger global market. Therefore, under the same competitive environment, foreign businessmen can obtain more profits and be more competitive than domestic manufacturers.
The reporter noted that before the centralized purchase of medicine, some foreign enterprises failed to match the quotations of mainland enterprises, resulting in the final abandonment of the bid. Is it possible for this to happen again in coronary stent harvesting?
Zhan Jincheng believes that even if the price ceiling of 2850 yuan, enterprises still have their own profit space. But the import manufacturers suddenly reduce the price to the same level as the local brands. They dont need to get the maximum quantity. Its good to have a certain market share. Chinas market is also a very important market for foreign investors. If we do not do it at all, the turnover and profits will suddenly decrease a lot, and the pressure on foreign businessmen will be even greater. .
It is worth noting that personnel from domestic coronary stent manufacturers said that it is not the manufacturers who are most affected by this round of centralized purchase, but the agents whose profit space is further compressed. Zhan Jincheng also believes that with the development of centralized purchasing, small agents will be merged by large pharmaceutical distributors or will become a trend.
After coronary stenting, it is a consensus that more high-value medical consumables should be included in the national procurement, and some places are exploring. For example, the second batch of high-value medical consumables in Anhui Province, such as orthopedic joint products and cardiac pacemakers, were successfully purchased, with an average decrease of 81.97% for 240 orthopedic joint products and 46.75% for 82 cardiac pacemakers. Reporter, Hua angjin, editor, Chen Junjie, Lu Xiangyong, Du Bo proofread, he Xiaotaos extended reading, and Goldman Sachs has recognized its failure again! Will pay more than $2 billion to the U.S. Department of justice to absolve Zhao Benshan, who once spoke for Huoxiang Zhengqi king for 10 years, losing 2 billion or changing ownership_ NF4368
After coronary stenting, it is a consensus that more high-value medical consumables should be included in the national procurement, and some places are exploring. For example, the second batch of high-value medical consumables in Anhui Province, such as orthopedic joint products and cardiac pacemakers, were successfully purchased, with an average decrease of 81.97% for 240 orthopedic joint products and 46.75% for 82 cardiac pacemakers.